335 related articles for article (PubMed ID: 32026557)
1. Insulin-like growth factor-II and bioactive proteins containing a part of the E-domain of pro-insulin-like growth factor-II.
van Doorn J
Biofactors; 2020 Jul; 46(4):563-578. PubMed ID: 32026557
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of the concentrations of IGFs and several IGF-binding proteins in a large fibrous abdominal tumor and the circulation of a patient with hypoglycemia.
van Doorn J; van de Hoef W; Dullaart RP
Biofactors; 2015 May; 41(3):183-9. PubMed ID: 26073062
[TBL] [Abstract][Full Text] [Related]
3. Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis.
Khosla S; Ballard FJ; Conover CA
J Clin Endocrinol Metab; 2002 Aug; 87(8):3867-70. PubMed ID: 12161524
[TBL] [Abstract][Full Text] [Related]
4. Probing Receptor Specificity by Sampling the Conformational Space of the Insulin-like Growth Factor II C-domain.
Hexnerová R; Křížková K; Fábry M; Sieglová I; Kedrová K; Collinsová M; Ullrichová P; Srb P; Williams C; Crump MP; Tošner Z; Jiráček J; Veverka V; Žáková L
J Biol Chem; 2016 Sep; 291(40):21234-21245. PubMed ID: 27510031
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the lower affinity of the insulin-like growth factors for the insulin receptor.
Gauguin L; Klaproth B; Sajid W; Andersen AS; McNeil KA; Forbes BE; De Meyts P
J Biol Chem; 2008 Feb; 283(5):2604-13. PubMed ID: 18048361
[TBL] [Abstract][Full Text] [Related]
6. Column chromatographic characterization of complex formation of pro-IGF-II isoforms with acid labile subunit and IGF-binding proteins associated with non-islet cell tumour induced hypoglycaemia.
van Veggel KM; Huits RM; Donker GH; Lentjes EG; van Doorn J
Growth Horm IGF Res; 2014 Dec; 24(6):233-8. PubMed ID: 25174810
[TBL] [Abstract][Full Text] [Related]
7. The expression and characterization of human recombinant proinsulin-like growth factor II and a mutant that is defective in the O-glycosylation of its E domain.
Yang CQ; Zhan X; Hu X; Kondepudi A; Perdue JF
Endocrinology; 1996 Jul; 137(7):2766-73. PubMed ID: 8770896
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycaemia associated with the production of insulin-like growth factor II and insulin-like growth factor binding protein 6 by a haemangiopericytoma.
Hoekman K; van Doorn J; Gloudemans T; Maassen JA; Schuller AG; Pinedo HM
Clin Endocrinol (Oxf); 1999 Aug; 51(2):247-53. PubMed ID: 10468998
[TBL] [Abstract][Full Text] [Related]
9. Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia.
van Doorn J; Hoogerbrugge CM; Koster JG; Bloemen RJ; Hoekman K; Mudde AH; van Buul-Offers SC
Clin Chem; 2002 Oct; 48(10):1739-50. PubMed ID: 12324491
[TBL] [Abstract][Full Text] [Related]
10. Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.
Daughaday WH; Trivedi B; Baxter RC
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5823-7. PubMed ID: 7685912
[TBL] [Abstract][Full Text] [Related]
11. Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in Cited1 mutant mice.
Novitskaya T; Baserga M; de Caestecker MP
Endocrinology; 2011 Jun; 152(6):2503-16. PubMed ID: 21486933
[TBL] [Abstract][Full Text] [Related]
12. Gene expression and serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins in a case of non-islet cell tumour hypoglycaemia.
Holt RI; Teale JD; Jones JS; Quin JD; McGregor AM; Miell JP
Growth Horm IGF Res; 1998 Dec; 8(6):447-54. PubMed ID: 10985756
[TBL] [Abstract][Full Text] [Related]
13. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive.
Dynkevich Y; Rother KI; Whitford I; Qureshi S; Galiveeti S; Szulc AL; Danoff A; Breen TL; Kaviani N; Shanik MH; Leroith D; Vigneri R; Koch CA; Roth J
Endocr Rev; 2013 Dec; 34(6):798-826. PubMed ID: 23671155
[TBL] [Abstract][Full Text] [Related]
14. Characterization of proinsulin-like growth factor-II E-region immunoreactivity in serum and other biological fluids.
Liu F; Baker BK; Powell DR; Hintz RL
J Clin Endocrinol Metab; 1993 May; 76(5):1095-100. PubMed ID: 8496298
[TBL] [Abstract][Full Text] [Related]
15. Insulin-Insulin-like Growth Factors Hybrids as Molecular Probes of Hormone:Receptor Binding Specificity.
Křížková K; Chrudinová M; Povalová A; Selicharová I; Collinsová M; Vaněk V; Brzozowski AM; Jiráček J; Žáková L
Biochemistry; 2016 May; 55(21):2903-13. PubMed ID: 27171135
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells.
Sarfstein R; Pasmanik-Chor M; Yeheskel A; Edry L; Shomron N; Warman N; Wertheimer E; Maor S; Shochat L; Werner H
J Biol Chem; 2012 Jan; 287(4):2766-76. PubMed ID: 22128190
[TBL] [Abstract][Full Text] [Related]
17. [The structural organization of binding determinants in insulin-like growth factor-I (IGF-I) molecule].
Kolychev AP
Zh Evol Biokhim Fiziol; 2010; 46(1):74-94. PubMed ID: 20297673
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactive proinsulin-like growth factor-II levels in healthy subjects, patients with growth hormone deficiency, and patients with type 1 diabetes: effects of insulin-like growth factor-I and insulin.
Tally M; Eriksson U; Thorén M; Brismar K; Hall K
J Clin Endocrinol Metab; 1994 Dec; 79(6):1576-81. PubMed ID: 7989458
[TBL] [Abstract][Full Text] [Related]
19. Abnormal processing of pro-IGF-II in patients with hepatoma and in some hepatitis B virus antibody-positive asymptomatic individuals.
Daughaday WH; Wu JC; Lee SD; Kapadia M
J Lab Clin Med; 1990 Oct; 116(4):555-62. PubMed ID: 2170553
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR.
Denley A; Bonython ER; Booker GW; Cosgrove LJ; Forbes BE; Ward CW; Wallace JC
Mol Endocrinol; 2004 Oct; 18(10):2502-12. PubMed ID: 15205474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
